Captrust Financial Advisors Makes New Investment in Biohaven Ltd. (NYSE:BHVN)

Captrust Financial Advisors purchased a new stake in Biohaven Ltd. (NYSE:BHVN) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 5,862 shares of the company’s stock, valued at approximately $293,000.

Several other institutional investors and hedge funds also recently made changes to their positions in BHVN. SG Americas Securities LLC boosted its stake in Biohaven by 114.6% in the 2nd quarter. SG Americas Securities LLC now owns 25,255 shares of the company’s stock worth $877,000 after purchasing an additional 13,485 shares during the period. Canton Hathaway LLC grew its holdings in shares of Biohaven by 2.3% during the second quarter. Canton Hathaway LLC now owns 21,850 shares of the company’s stock worth $758,000 after buying an additional 500 shares in the last quarter. Bank of New York Mellon Corp raised its position in Biohaven by 30.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 321,127 shares of the company’s stock valued at $11,146,000 after buying an additional 74,490 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Biohaven by 4.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,431 shares of the company’s stock valued at $605,000 after acquiring an additional 778 shares in the last quarter. Finally, Panagora Asset Management Inc. acquired a new position in Biohaven during the 2nd quarter worth approximately $6,945,000. Institutional investors and hedge funds own 88.78% of the company’s stock.

Insider Transactions at Biohaven

In other news, Director John W. Childs acquired 21,052 shares of the stock in a transaction on Wednesday, October 2nd. The shares were purchased at an average price of $47.50 per share, for a total transaction of $999,970.00. Following the transaction, the director now directly owns 21,052 shares of the company’s stock, valued at approximately $999,970. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gregory Bailey bought 5,000 shares of the company’s stock in a transaction dated Tuesday, September 24th. The shares were purchased at an average cost of $44.19 per share, with a total value of $220,950.00. Following the acquisition, the director now directly owns 1,620,071 shares of the company’s stock, valued at approximately $71,590,937.49. This represents a 0.31 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 16.00% of the company’s stock.

Biohaven Trading Down 4.2 %

BHVN opened at $38.47 on Friday. The stock’s fifty day simple moving average is $48.70 and its 200 day simple moving average is $41.77. Biohaven Ltd. has a 1-year low of $26.80 and a 1-year high of $62.21. The stock has a market cap of $3.89 billion, a PE ratio of -4.11 and a beta of 1.24.

Biohaven (NYSE:BHVN) last posted its earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03). Equities analysts forecast that Biohaven Ltd. will post -8.85 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BHVN. Leerink Partners boosted their price objective on shares of Biohaven from $55.00 to $60.00 and gave the stock an “outperform” rating in a research report on Monday, September 23rd. TD Cowen lifted their price target on shares of Biohaven from $55.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. increased their price objective on shares of Biohaven from $55.00 to $68.00 and gave the stock an “overweight” rating in a research note on Thursday, October 3rd. Sanford C. Bernstein lifted their target price on Biohaven from $55.00 to $66.00 and gave the company an “outperform” rating in a research report on Tuesday, September 24th. Finally, HC Wainwright reiterated a “buy” rating and set a $59.00 target price on shares of Biohaven in a report on Tuesday, November 26th. Thirteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $63.00.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.